Few disclosures on a life insurance application carry as much weight as a cancer history. For many agents, seeing cancer in a client's medical background triggers an assumption that the case is unplaceable or that the only option is a guaranteed issue product. That assumption is often wrong.
The reality is that many cancer survivors can obtain traditionally underwritten life insurance at reasonable rates. The key variables are the type of cancer, the stage at diagnosis, the treatment completed, and how much time has passed since treatment ended. Understanding these factors lets you serve a population that is often underserved and deeply motivated to secure coverage for their families.
Type of cancer matters enormously
Not all cancers are underwritten the same way. Carriers distinguish between cancers based on their recurrence risk, mortality rates, and typical treatment outcomes. Some cancers are viewed much more favorably than others.
Basal cell skin cancer, for example, is generally a non-issue for underwriting purposes. Most carriers will offer standard or preferred rates for basal cell carcinoma with no waiting period after treatment, because recurrence is easily managed and mortality risk is negligible.
Early-stage thyroid cancer, early-stage prostate cancer, and certain early-stage breast cancers are also viewed relatively favorably by most carriers, especially when treatment was successful and sufficient time has passed. These cancers have high survival rates and well-established treatment protocols.
On the other end of the spectrum, pancreatic cancer, late-stage lung cancer, and metastatic cancers of any type are underwritten much more conservatively. Depending on the stage and recurrence risk, some of these may result in a decline or a very long postponement period before coverage is considered.
Time since treatment completion
The single most important timeline factor for cancer underwriting is how long it has been since the client completed treatment, including any adjuvant therapy like chemotherapy or radiation. Most carriers require a minimum waiting period before they will consider a traditionally underwritten application.
For more favorable cancer types diagnosed at early stages, some carriers will consider applications as soon as one year after treatment completion. For moderate-risk cancers, the typical waiting period is two to three years. For higher-risk cancers, carriers may require five years or more of clean follow-up before they will offer coverage.
During the waiting period, the client is not necessarily without options. Some carriers offer graded or modified benefit policies that provide coverage with certain limitations during the first few years. These can serve as a bridge until the client qualifies for full traditional coverage.
Stage at diagnosis and treatment details
Staging is critical in cancer underwriting. A Stage I breast cancer treated with lumpectomy and radiation has a fundamentally different risk profile than a Stage III breast cancer requiring mastectomy, chemotherapy, and ongoing hormonal therapy. Carriers evaluate the stage at diagnosis, the type of treatment received, whether lymph nodes were involved, and the pathology details.
As an agent, you do not need to be an oncologist, but you should ask your client about their diagnosis in enough detail to pre-qualify the case. Key questions include what type of cancer it was, what stage it was at diagnosis, what treatment they received, when treatment ended, and what their follow-up schedule and most recent results look like.
Flat extras versus table ratings
Cancer cases are often approved with either a flat extra charge or a table rating, or sometimes both. A flat extra is an additional charge per thousand dollars of coverage, typically applied for a defined period of time, such as five years. After that period, if the client remains cancer-free, the flat extra is removed and the premium drops.
Table ratings increase the standard premium by a percentage, and they are applied when the overall risk is elevated but not high enough to decline. Understanding these rating structures helps you set appropriate expectations with your client. A policy with a temporary flat extra of five to ten dollars per thousand may look expensive initially, but it is still dramatically better than a guaranteed issue product, and the extra drops off over time.
How to work cancer cases
The most important step is to pre-screen the case before submitting a formal application. Informal inquiries allow you to present the cancer details to multiple carriers and get preliminary indications of how they would rate the case, without creating a record of formal application activity. This is especially important for cancer survivors because a formal decline goes on the MIB record and can complicate future applications.
Work with your brokerage general agency if you have one. Experienced underwriting consultants can help you identify which carriers have the most favorable guidelines for specific cancer types and stages. Carrier appetite varies significantly, and the right carrier match can mean the difference between a table D rating and a decline.
Gather as much medical documentation as you can before submitting. Pathology reports, treatment summaries, and recent follow-up labs or imaging results help the underwriter make a faster and more favorable decision. Incomplete information leads to delays and often more conservative outcomes.
Setting expectations with your client
Be honest with cancer survivor clients about the process. It may take longer than a standard case. There may be a rating or flat extra involved. The first carrier you try may not offer the best terms. But for many cancer survivors, the ability to get traditionally underwritten coverage at all is a significant relief, and they are often among the most grateful and loyal clients you will have.
Closd helps you manage complex cases across multiple carriers and track every application from submission to issue. Start your free trial at getclosdai.com